Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics.

Torka P, Kothari SK, Sundaram S, Li S, Medeiros LJ, Ayers EC, Landsburg DJ, Bond DA, Maddocks KJ, Giri A, Hess B, Pham LQ, Advani R, Liu Y, Barta SK, Vose JM, Churnetski MC, Cohen JB, Burkart M, Karmali R, Zurko J, Mehta A, Olszewski AJ, Lee S, Hill BT, Burns TF, Lansigan F, Rabinovich E, Peace D, Groman A, Attwood K, Hernandez-Ilizaliturri FJ.

Blood Adv. 2020 Jan 28;4(2):253-262. doi: 10.1182/bloodadvances.2019000875.

PMID:
31945157
2.

NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020.

Becker PS, Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Dinner S, Gojo I, Hicks A, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Landsburg D, Lyman GH, Miller R, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Rosovsky R, Roy V, Rugo HS, Shayani S, Vasu S, Wadleigh M, Westbrook K, Westervelt P, Burns J, Keller J, Pluchino LA.

J Natl Compr Canc Netw. 2020 Jan;18(1):12-22. doi: 10.6004/jnccn.2020.0002.

PMID:
31910384
3.

Management and outcomes of sinus histiocytosis with massive lymphadenopathy (Rosai Dorfman Disease).

Namoglu EC, Hughes ME, Plastaras JP, Landsburg DJ, Maity A, Nasta SD.

Leuk Lymphoma. 2019 Dec 26:1-7. doi: 10.1080/10428194.2019.1703971. [Epub ahead of print]

PMID:
31876204
4.

Deletion 20q12 is associated with histological transformation of nodal marginal zone lymphoma to diffuse large B-cell lymphoma.

Qian L, Soderquist C, Schrank-Hacker A, Strauser H, Dupoux V, Tang CN, Smith JR, Sun A, Majumdar S, Nguyen T, Widura S, Landsburg DJ, Schuster SJ, Baxter RHG, Bogusz AM.

Am J Hematol. 2019 Dec 5. doi: 10.1002/ajh.25694. [Epub ahead of print]

PMID:
31804739
5.

Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy.

Landsburg DJ, Ayers EC, Bond DA, Maddocks KJ, Karmali R, Behdad A, Curry M, Wagner-Johnston ND, Modi D, Ramchandren R, Assouline SE, Faramand R, Chavez JC, Torka P, Mier Hicks A, Medeiros LJ, Li S.

Br J Haematol. 2019 Dec 5. doi: 10.1111/bjh.16319. [Epub ahead of print]

PMID:
31804715
6.

Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma With Venetoclax: A Single-Center Evaluation of Off-Label Use.

Hughes ME, Landsburg DJ, Rubin DJ, Schuster SJ, Svoboda J, Gerson JN, Namoglu E, Nasta SD.

Clin Lymphoma Myeloma Leuk. 2019 Dec;19(12):791-798. doi: 10.1016/j.clml.2019.09.612. Epub 2019 Sep 28.

PMID:
31648953
7.

Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.

Ayers EC, Li S, Medeiros LJ, Bond DA, Maddocks KJ, Torka P, Mier Hicks A, Curry M, Wagner-Johnston ND, Karmali R, Behdad A, Fakhri B, Kahl BS, Churnetski MC, Cohen JB, Reddy NM, Modi D, Ramchandren R, Howlett C, Leslie LA, Cytryn S, Diefenbach CS, Faramand R, Chavez JC, Olszewski AJ, Liu Y, Barta SK, Mukhija D, Hill BT, Ma H, Amengual JE, Nathan S, Assouline SE, Orellana-Noia VM, Portell CA, Chandar A, David KA, Giri A, Hess BT, Landsburg DJ.

Cancer. 2020 Jan 15;126(2):293-303. doi: 10.1002/cncr.32526. Epub 2019 Sep 30.

PMID:
31568564
8.

Guideline implementation is effective at reducing proton pump inhibitor use in hematology-oncology units: A multidisciplinary intervention for reducing Clostridioides difficile risk.

Ziegler MJ, Freyer C, Landsburg D, Pegues D, Bilker W, Hirsh R, Kucharczuk C, Gilmar C, Gorman T, Palmer M, Harker C, Lightheart E, Han JH.

Infect Control Hosp Epidemiol. 2019 Nov;40(11):1294-1296. doi: 10.1017/ice.2019.238. Epub 2019 Aug 30.

PMID:
31466535
9.

Impact of Levofloxacin for the Prophylaxis of Bloodstream Infection on the Gut Microbiome in Patients With Hematologic Malignancy.

Ziegler M, Han JH, Landsburg D, Pegues D, Reesey E, Gilmar C, Gorman T, Bink K, Moore A, Kelly BJ; CDC Prevention Epicenters Program.

Open Forum Infect Dis. 2019 May 31;6(7):ofz252. doi: 10.1093/ofid/ofz252. eCollection 2019 Jul.

10.

Survival outcomes of diffuse large B-cell lymphoma by association with concurrent or antecedent follicular lymphoma and double hit status.

Behdad A, Boddy CS, Fought AJ, Taxter T, Falkiewicz MK, Ayers E, Chen QC, Chen YH, Karmali R, Pro B, Winter JN, Landsburg DJ, Gordon LI, Kaplan JB.

Leuk Lymphoma. 2019 Dec;60(13):3266-3271. doi: 10.1080/10428194.2019.1622099. Epub 2019 Jun 21.

PMID:
31225766
11.

Nutrition-Related Outcomes for Autologous Stem Cell Transplantation Patients.

Lazarow H, Nicolo M, Compher C, Kucharczuk CR, Stadtmauer EA, Landsburg DJ.

Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):e393-e398. doi: 10.1016/j.clml.2019.04.002. Epub 2019 Apr 6.

PMID:
31053549
12.

Hodgkin lymphoma patients have an increased incidence of idiopathic acquired aplastic anemia.

Linaburg T, Davis AR, Frey NV, Khawaja MR, Landsburg DJ, Schuster SJ, Svoboda J, Li Y, Borovskiy Y, Olson TS, Bagg A, Hexner EO, Babushok DV.

PLoS One. 2019 Apr 5;14(4):e0215021. doi: 10.1371/journal.pone.0215021. eCollection 2019.

13.

Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy.

Landsburg DJ, Hughes ME, Koike A, Bond D, Maddocks KJ, Guo L, Winter AM, Hill BT, Ondrejka SL, Hsi ED, Nasta SD, Svoboda J, Schuster SJ, Bogusz AM.

Blood Adv. 2019 Jan 22;3(2):132-135. doi: 10.1182/bloodadvances.2018026401. No abstract available.

14.

Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.

Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, Medeiros LJ, Wang MI, Cohen JB, Calzada O, Churnetski MC, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, Vose JM, Bast MA, Fenske TS, Narayana Rao Gari S, Maddocks KJ, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns TF, Donovan AM, Wagner-Johnston N, Messmer M, Mehta A, Anderson JK, Reddy N, Kovach AE, Landsburg DJ, Glenn M, Inwards DJ, Karmali R, Kaplan JB, Caimi PF, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual JE, Lue JK, Diefenbach C, Fisher RI, Barta SK.

J Clin Oncol. 2019 Feb 20;37(6):471-480. doi: 10.1200/JCO.18.00690. Epub 2019 Jan 7.

PMID:
30615550
15.

Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.

Bair SM, Strelec LE, Feldman TA, Ahmed G, Armand P, Shah NN, Singavi AN, Reddy N, Khan N, Andreadis C, Vu K, Huntington SF, Giri S, Ujjani C, Howlett C, Faheem M, Youngman MR, Nasta SD, Landsburg DJ, Schuster SJ, Svoboda J.

Oncologist. 2019 Jul;24(7):955-962. doi: 10.1634/theoncologist.2018-0538. Epub 2018 Dec 19.

16.

Can We Exploit the Molecular Heterogeneity of Aggressive B Cell Lymphomas Into Effective New Therapies?

Landsburg DJ, Kahl BS.

Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):65-67. doi: 10.1016/j.clml.2018.11.017. Epub 2018 Nov 24. No abstract available.

PMID:
30555036
17.

Fluoroquinolone Prophylaxis Is Highly Effective for the Prevention of Central Line-Associated Bloodstream Infections in Autologous Stem Cell Transplant Patients.

Ziegler M, Landsburg D, Pegues D, Bilker W, Gilmar C, Kucharczuk C, Gorman T, Bink K, Moore A, Fitzpatrick R, Stadtmauer EA, Mangan P, Kraus K, Han JH.

Biol Blood Marrow Transplant. 2019 May;25(5):1004-1010. doi: 10.1016/j.bbmt.2018.11.023. Epub 2018 Nov 24.

PMID:
30481595
18.

Bexarotene in Patients With Peripheral T-cell Lymphomas: Results of a Retrospective Study.

Farhan A, Chong EA, Schuster SJ, Strelec L, Nasta SD, Landsburg D, Svoboda J.

Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):109-115. doi: 10.1016/j.clml.2018.10.001. Epub 2018 Oct 13.

PMID:
30448048
19.

Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas.

Shah NN, Nagle SJ, Torigian DA, Farwell MD, Hwang WT, Frey N, Nasta SD, Landsburg D, Mato A, June CH, Schuster SJ, Porter DL, Svoboda J.

Cytotherapy. 2018 Dec;20(12):1415-1418. doi: 10.1016/j.jcyt.2018.10.003. Epub 2018 Oct 29.

PMID:
30385043
20.

Long-term outcomes of rituximab, temozolomide and high-dose methotrexate without consolidation therapy for lymphoma involving the CNS.

Nagle SJ, Shah NN, Ganetsky A, Landsburg DJ, Nasta SD, Mato A, Schuster SJ, Reshef R, Tsai DE, Svoboda J.

Int J Hematol Oncol. 2017 Dec;6(4):113-121. doi: 10.2217/ijh-2017-0020. Epub 2018 Jan 26.

21.

Small-Molecule Inhibitors for the Treatment of Diffuse Large B Cell Lymphoma.

Rhodes J, Landsburg DJ.

Curr Hematol Malig Rep. 2018 Oct;13(5):356-368. doi: 10.1007/s11899-018-0467-5. Review.

PMID:
30112707
22.

Interim PET/CT Result Is Not Predictive of Survival in Patients With MYC-rearranged Non-Burkitt Aggressive B-cell Lymphoma.

Cherng HJ, Sargent RL, Nasta SD, Svoboda J, Schuster SJ, Mato AR, Schrank-Hacker A, Morrissette JJD, Landsburg DJ.

Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):673-678. doi: 10.1016/j.clml.2018.06.012. Epub 2018 Jun 15.

PMID:
30033208
23.

Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma.

Svoboda J, Rheingold SR, Gill SI, Grupp SA, Lacey SF, Kulikovskaya I, Suhoski MM, Melenhorst JJ, Loudon B, Mato AR, Nasta SD, Landsburg DJ, Youngman MR, Levine BL, Porter DL, June CH, Schuster SJ.

Blood. 2018 Sep 6;132(10):1022-1026. doi: 10.1182/blood-2018-03-837609. Epub 2018 Jun 20.

PMID:
29925499
24.

Clinical Characteristics and Outcomes of Hematologic Malignancy Patients With Positive Clostridium difficile Toxin Immunoassay Versus Polymerase Chain Reaction Test Results.

Ziegler M, Landsburg D, Pegues D, Alby K, Gilmar C, Bink K, Gorman T, Moore A, Bonhomme B, Omorogbe J, Tango D, Tolomeo P, Han JH.

Infect Control Hosp Epidemiol. 2018 Jul;39(7):863-866. doi: 10.1017/ice.2018.83. Epub 2018 Apr 25.

25.

Adult nodular lymphocyte-predominant Hodgkin lymphoma: treatment modality utilization and survival.

Alonso C, Dutta SW, Mitra N, Landsburg DJ, Zaorsky NG, Grover S, Peterson J, Trifiletti DM.

Cancer Med. 2018 Apr;7(4):1118-1126. doi: 10.1002/cam4.1383. Epub 2018 Feb 26.

26.

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.

Mato AR, Nabhan C, Thompson MC, Lamanna N, Brander DM, Hill B, Howlett C, Skarbnik A, Cheson BD, Zent C, Pu J, Kiselev P, Goy A, Claxton D, Isaac K, Kennard KH, Timlin C, Landsburg D, Winter A, Nasta SD, Bachow SH, Schuster SJ, Dorsey C, Svoboda J, Barr P, Ujjani CS.

Haematologica. 2018 May;103(5):874-879. doi: 10.3324/haematol.2017.182907. Epub 2018 Feb 1.

27.

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.

Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, Wasik M, Levine BL, Lacey SF, Melenhorst JJ, Porter DL, June CH.

N Engl J Med. 2017 Dec 28;377(26):2545-2554. doi: 10.1056/NEJMoa1708566. Epub 2017 Dec 10.

28.

Treatment of CD30-Negative Refractory Mycosis Fungoides With Brentuximab Vedotin.

Zhang C, Chairatchaneeboon M, Haun P, Landsburg D, Kim EJ.

JAMA Dermatol. 2018 Jan 1;154(1):109-110. doi: 10.1001/jamadermatol.2017.3961. No abstract available.

PMID:
29167875
29.

Advancing the management of double hit lymphoma.

Landsburg DJ.

Oncotarget. 2017 Sep 9;8(45):78245-78246. doi: 10.18632/oncotarget.20794. eCollection 2017 Oct 3. No abstract available.

30.

A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib.

Winter AM, Landsburg DJ, Mato AR, Isaac K, Hernandez-Ilizaliturri FJ, Reddy N, Smith S, Shadman M, Smith MR, Caimi P, Jagadeesh D, Hill BT.

Blood. 2017 Oct 5;130(14):1676-1679. doi: 10.1182/blood-2017-05-786988. No abstract available.

PMID:
28794071
31.

Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis.

Bair SM, Strelec L, Nagle SJ, Nasta SD, Landsburg DJ, Mato AR, Loren AW, Schuster SJ, Stadtmauer EA, Svoboda J.

Am J Hematol. 2017 Sep;92(9):879-884. doi: 10.1002/ajh.24792. Epub 2017 Jun 9.

32.

Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission.

Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, Mato AR, Hill BT, Li S, Medeiros LJ, Torka P, Hernandez-Ilizaliturri F, Reddy NM, Singavi A, Fenske TS, Chavez JC, Kaplan JB, Behdad A, Petrich AM, Bast MA, Vose JM, Olszewski AJ, Costa C, Lansigan F, Gerson JN, Barta SK, Calzada O, Cohen JB, Lue JK, Amengual JE, Rivera X, Persky DO, Peace DJ, Nathan S, Cassaday RD.

J Clin Oncol. 2017 Jul 10;35(20):2260-2267. doi: 10.1200/JCO.2017.72.2157. Epub 2017 May 5.

33.

Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.

Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, Skarbnik AP, Howlett C, Pu JJ, Sehgal AR, Strelec LE, Vandegrift A, Fitzpatrick DM, Zent CS, Feldman T, Goy A, Claxton DF, Bachow SH, Kaur G, Svoboda J, Nasta SD, Porter D, Landsburg DJ, Schuster SJ, Cheson BD, Kiselev P, Evens AM.

Blood. 2016 Nov 3;128(18):2199-2205. Epub 2016 Sep 6.

PMID:
27601462
34.

Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.

Landsburg DJ, Falkiewicz MK, Petrich AM, Chu BA, Behdad A, Li S, Medeiros LJ, Cassaday RD, Reddy NM, Bast MA, Vose JM, Kruczek KR, Smith SE, Patel P, Hernandez-Ilizaliturri F, Karmali R, Rajguru S, Yang DT, Maly JJ, Blum KA, Zhao W, Vanslambrouck C, Nabhan C.

Br J Haematol. 2016 Nov;175(4):631-640. doi: 10.1111/bjh.14282. Epub 2016 Jul 29.

35.

Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas.

Yam C, Landsburg DJ, Nead KT, Lin X, Mato AR, Svoboda J, Loren AW, Frey NV, Stadtmauer EA, Porter DL, Schuster SJ, Nasta SD.

Am J Hematol. 2016 Jul;91(7):672-6. doi: 10.1002/ajh.24372. Epub 2016 Apr 24.

36.

Management of Patients with MYC-Altered Lymphomas.

Landsburg DJ.

Curr Hematol Malig Rep. 2016 Jun;11(3):208-17. doi: 10.1007/s11899-016-0320-7. Review.

PMID:
26983958
37.

Who Should Be Tested for Double-Hit Lymphoma?

Landsburg DJ, Schuster SJ.

J Oncol Pract. 2016 Mar;12(3):243-4. doi: 10.1200/JOP.2015.010595. No abstract available.

PMID:
26962169
38.

Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.

Landsburg DJ, Petrich AM, Abramson JS, Sohani AR, Press O, Cassaday R, Chavez JC, Song K, Zelenetz AD, Gandhi M, Shah N, Fenske TS, Jaso J, Medeiros LJ, Yang DT, Nabhan C.

Cancer. 2016 Feb 15;122(4):559-64. doi: 10.1002/cncr.29781. Epub 2015 Nov 13.

39.

Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma.

Luskin MR, Ganetsky A, Landsburg DJ, Loren AW, Porter DL, Nasta SD, Svoboda J, Luger SM, Frey NV.

Br J Haematol. 2016 Jul;174(2):332-4. doi: 10.1111/bjh.13771. Epub 2015 Sep 25. No abstract available.

PMID:
26403537
40.

Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis.

Howlett C, Snedecor SJ, Landsburg DJ, Svoboda J, Chong EA, Schuster SJ, Nasta SD, Feldman T, Rago A, Walsh KM, Weber S, Goy A, Mato A.

Br J Haematol. 2015 Aug;170(4):504-14. doi: 10.1111/bjh.13463. Epub 2015 Apr 24. Review.

PMID:
25907897
41.

Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma.

Vij R, Kumar S, Zhang MJ, Zhong X, Huang J, Dispenzieri A, Abidi MH, Bird JM, Freytes CO, Gale RP, Kindwall-Keller TL, Kyle RA, Landsburg DJ, Lazarus HM, Munker R, Roy V, Sharma M, Vogl DT, Wirk B, Hari PN.

Biol Blood Marrow Transplant. 2015 Feb;21(2):335-41. doi: 10.1016/j.bbmt.2014.10.023. Epub 2014 Nov 1.

42.

R-CHOP or R-HyperCVAD with or without autologous stem cell transplantation for older patients with mantle cell lymphoma.

Frosch Z, Luskin MR, Landsburg DJ, Schuster SJ, Svoboda J, Loren AW, Porter DL, Stadtmauer EA, Nasta SD.

Clin Lymphoma Myeloma Leuk. 2015 Feb;15(2):92-7. doi: 10.1016/j.clml.2014.07.017. Epub 2014 Aug 1.

PMID:
25174772
43.

Melphalan/total body irradiation-conditioned myeloablative allogeneic hematopoietic cell transplantation for patients with primary plasma cell leukemia.

Landsburg DJ, Vogl DT, Plastaras JP, Stadtmauer EA.

Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):e225-8. doi: 10.1016/j.clml.2014.07.012. Epub 2014 Aug 2. No abstract available.

PMID:
25172535
44.

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.

Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan F, Hernandez-Ilizaliturri FJ, Lee LX, Barta SK, Melinamani S, Karmali R, Adeimy C, Smith S, Dalal N, Nabhan C, Peace D, Vose J, Evens AM, Shah N, Fenske TS, Zelenetz AD, Landsburg DJ, Howlett C, Mato A, Jaglal M, Chavez JC, Tsai JP, Reddy N, Li S, Handler C, Flowers CR, Cohen JB, Blum KA, Song K, Sun HL, Press O, Cassaday R, Jaso J, Medeiros LJ, Sohani AR, Abramson JS.

Blood. 2014 Oct 9;124(15):2354-61. doi: 10.1182/blood-2014-05-578963. Epub 2014 Aug 26.

PMID:
25161267
45.

Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project.

Carson KR, Newsome SD, Kim EJ, Wagner-Johnston ND, von Geldern G, Moskowitz CH, Moskowitz AJ, Rook AH, Jalan P, Loren AW, Landsburg D, Coyne T, Tsai D, Raisch DW, Norris LB, Bookstaver PB, Sartor O, Bennett CL.

Cancer. 2014 Aug 15;120(16):2464-71. doi: 10.1002/cncr.28712. Epub 2014 Apr 25.

46.

'Double-Hit' cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients.

Landsburg DJ, Nasta SD, Svoboda J, Morrissette JJ, Schuster SJ.

Br J Haematol. 2014 Aug;166(3):369-74. doi: 10.1111/bjh.12901. Epub 2014 Apr 25.

PMID:
24761809
47.

Could treatment with R-HCVAD/R-MA as compared to R-CHOP truly result in improved outcomes for patients with high-risk diffuse large B cell lymphoma?

Landsburg DJ, Schuster SJ, Svoboda J, Nasta SD.

Br J Haematol. 2014 Apr;165(1):145-6. doi: 10.1111/bjh.12702. Epub 2013 Dec 19. No abstract available.

PMID:
24354694
48.

Receipt of maintenance therapy is most predictive of survival in older acute lymphoblastic leukemia patients treated with intensive induction chemotherapy regimens.

Landsburg DJ, Stadtmauer E, Loren A, Goldstein S, Frey N, Nasta SD, Porter DL, Tsai DE, Perl AE, Hexner EO, Luger S.

Am J Hematol. 2013 Aug;88(8):657-60. doi: 10.1002/ajh.23468. Epub 2013 Jun 5.

49.

Contribution of cysteine residues to the structure and function of herpes simplex virus gH/gL.

Cairns TM, Landsburg DJ, Whitbeck JC, Eisenberg RJ, Cohen GH.

Virology. 2005 Feb 20;332(2):550-62.

50.

Potential nectin-1 binding site on herpes simplex virus glycoprotein d.

Connolly SA, Landsburg DJ, Carfi A, Whitbeck JC, Zuo Y, Wiley DC, Cohen GH, Eisenberg RJ.

J Virol. 2005 Jan;79(2):1282-95.

Supplemental Content

Loading ...
Support Center